Clinical Trial Update: Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the addition of cetuximab to radiotherapy and standard treatment for resectable esophageal adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: P.O. Witteveen | Conditions: Resectable Esophageal Cancer | Phase 2 | Status: TERMINATED